Used in solid-phase peptide synthesis as a protected glycosylated amino acid building block. Enables the incorporation of complex sugar-modified threonine residues into peptides, particularly for studying glycopeptide structure and function. Commonly applied in the development of bioactive glycopeptide analogs, including those with therapeutic potential in immunology and oncology. The acetyl groups protect hydroxyl functionalities during synthesis and can be removed selectively to allow further glycan modification. The Fmoc group allows for mild base-labile deprotection, making it compatible with standard Fmoc-strategy protocols.